EFFECTS OF CARVEDILOL ON RENAL-FUNCTION

被引:25
作者
DUPONT, AG
机构
[1] Department of Internal Medicine, University Hospital Vrije Universiteit, Brussels, B-1090
关键词
carvedilol; essential hypertension; renal haemodynamics;
D O I
10.1007/BF01409473
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A randomized, double-blind, placebo-controlled study was conducted to study the effects of acute and chronic administration of carvedilol in essential hypertension, with special emphasis on renal haemodynamics and function. Acute administration of a single dose of 50 mg carvedilol reduced systolic and diastolic blood pressure without inducing reflex tachycardia. Renal blood flow was preserved; accordingly, renal vascular resistance was significantly reduced. A significant reduction in the glomerular filtration rate and filtration fraction was observed. Plasma renin activity (PRA) and plasma aldosterone values were not changed. Chronic carvedilol treatment produced a significant fall in systolic and diastolic blood pressure, heart rate, PRA and plasma aldosterone. Renal blood flow, glomerular filtration rate and filtration fraction also remained unchanged; renal vascular resistance decreased significantly. It is concluded that carvedilol possesses definite antihypertensive and renal vasodilating properties, both acutely and after chronic treatment. © 1990 Springer-Verlag.
引用
收藏
页码:S96 / S100
页数:5
相关论文
共 31 条
[1]  
ABSHAGEN U, 1987, Journal of Cardiovascular Pharmacology, V10, pS23, DOI 10.1097/00005344-198706111-00005
[2]  
BLAUFOX MD, 1989, EVALUATION RENAL FUN, P12
[3]  
BOCKRINGER K, 1983, BR J CLIN PHARM, V15, P181
[4]   EFFECTS OF LABETALOL AND METHYLDOPA ON RENAL-FUNCTION [J].
CRUZ, F ;
ONEILL, WM ;
CLIFTON, G ;
WALLIN, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 30 (01) :57-63
[5]  
DELEEUW PW, 1983, HDB HYPERTENSION, V1, P202
[6]   NADOLOL IN ESSENTIAL-HYPERTENSION - EFFECT ON AMBULATORY BLOOD-PRESSURE, RENAL HEMODYNAMICS AND CARDIAC-FUNCTION [J].
DUPONT, AG ;
VANDERNIEPEN, P ;
BOSSUYT, AM ;
JONCKHEER, MH ;
SIX, RO .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 20 (02) :93-99
[7]  
EGGERTSEN R, 1984, EUR J CLIN PHARMACOL, V27, P19, DOI 10.1007/BF02395200
[8]  
Eggertsen R, 1984, J Hypertens, V2, P529, DOI 10.1097/00004872-198410000-00013
[9]  
EGGERTSEN R, 1985, INT J CLIN PHARM TH, V23, P411
[10]  
EPSTEIN M, 1982, MINER ELECTROL METAB, V8, P237